hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06305897, orgStudyIdInfo id: CS5_10B, briefTitle: Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face, acronym: CS5_10B, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Cryonove Pharma, class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to compare the 3 different prototype of cyto-selective cryotherapy devices (name of the devices : CRYONOVE) use in brown spots on the face of subject from different ethnicities. The main questions it aims to answer are:* the tolerance of 3 prototypes of cyto-selective cryotherapy treatments* the performance of 3 prototypes of cyto-selective cryotherapy treatmentsParticipants will be treated for each spots with a definied prototype during 6 treatment visits.Researchers will compare the tolerance and performance of the 3 prototypes., conditionsModule conditions: Lentigo, conditions: Solar Lentigo, conditions: Post Inflammatory Hyperpigmentation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Proof of concept study concerning 3 prototypes of cyto-selective cryotherapy devices corresponding to a modified CE marked medical device (ref: 822-v1)., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: CRYONOVE (EC14_4osc), interventions name: CRYONOVE (EC+05_1osc), interventions name: CRYONOVE (EC+05_2osc), outcomesModule primaryOutcomes measure: Tolerance, secondaryOutcomes measure: Performance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06305884, orgStudyIdInfo id: OSU-21287, secondaryIdInfos id: NCI-2023-03077, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), briefTitle: Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Ohio State University Comprehensive Cancer Center, class: OTHER, descriptionModule briefSummary: This clinical trial studies how well new adhesive-based sensors that stick to the skin (transcutaneous) work in detecting cancer-related long-term arm swelling (lymphedema). For many patients, lymphedema s painful, unsightly, and weakening. The early signs of lymphedema are hard to see, and sometimes it is only diagnosed by hospital equipment at larger centers. Treating lymphedema early is usually more successful than trying to treat in later stages. The adhesive-based sensors used in this study work by using techniques called photoplethysmography (PPG) and bioimpedance (BI). PPG is an optical technique that can be used to detect blood volume changes in tissue. BI evaluates how tissue responds to an externally applied electrical current. This study may assist researchers in distinguishing participants with lymphedema in comparison to participants without lymphedema, and develop a way for patients to check for lymphedema at home., conditionsModule conditions: Hematopoietic and Lymphoid System Neoplasm, conditions: Lymphedema, conditions: Malignant Solid Neoplasm, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Bioelectric Impedance Analysis, interventions name: Exercise, interventions name: Photoplethysmography, interventions name: Questionnaire Administration, outcomesModule primaryOutcomes measure: Unique signature describing photoplethysmography and bioimpedance at rest and during activity, secondaryOutcomes measure: Patient reported outcomes, secondaryOutcomes measure: Tolerability of sensors, secondaryOutcomes measure: Likely classification for lymphedema, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ohio State University Comprehensive Cancer Center, city: Columbus, state: Ohio, zip: 43210, country: United States, contacts name: Carlo M. Contreras, MD, role: CONTACT, phone: 614-293-3465, email: Carlo.Contreras@osumc.edu, contacts name: Carlo M. Contreras, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.96118, lon: -82.99879, hasResults: False
protocolSection identificationModule nctId: NCT06305858, orgStudyIdInfo id: UKA - PFJ, briefTitle: Partial Versus Total Knee Replacement in Bicompartmental Gonarthrosis (Medial and Patellofemoral): Prospective Functional Assessment Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio, class: OTHER, descriptionModule briefSummary: The study is, in accordance with current legislation, definable as a prospective single-center interventional randomized study.The aim of the study is to evaluate the post-operative recovery of the group A patient undergoing the partial knee replacement surgical procedure compared to the group B patient undergoing the total knee replacement surgical procedure through clinical/functional scores.The primary outcome is evaluate the difference in score of the KSS questionnaire, at 1 month after surgery, completed by the patient of group A compared to the patient of group B.The population consists of 48 adult patients with gonarthrosis divided into two groups:24 patients Group A experimental group: partial denture surgical procedure24 patients Group B control group: total denture surgical procedure with patellar resurfacing, conditionsModule conditions: Knee Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Prosthetic Surgical Procedure, outcomesModule primaryOutcomes measure: Assess the difference in score of the KSS (Knee Society Score) questionnaire, completed by the patient in group A compared to the patient in group B, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istituto Clinico San Siro, status: RECRUITING, city: Milan, country: Italy, contacts name: Elena Cittera, role: CONTACT, phone: 0283502224, email: elena.cittera@grupposandonato.it, contacts name: Andrea Parente, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06305845, orgStudyIdInfo id: 152012023, briefTitle: Digital Crowns Versus Prefabricated Crowns on Primary Teeth, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-09-20, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: National Research Centre, Egypt, class: OTHER, descriptionModule briefSummary: Badly decayed primary molars will be treated by performing the pulp therapy technique indicated, then the patients will be randomized into two groups to receive the restorative intervention. For the intervention group, teeth will be prepared to receive the digital crown after intraoral scanning while for the control group, teeth will be prepared to receive the prefabricated zirconia crowns. Teeth will be followed up clinically for 1 year, at 1, 6 and 12 months., conditionsModule conditions: Dental Caries in Children, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: a randomized clinical trial with two parallel arms, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: participants will not be informed of which crown they will receive, whoMasked: PARTICIPANT, enrollmentInfo count: 58, type: ESTIMATED, armsInterventionsModule interventions name: Digital crowns, outcomesModule primaryOutcomes measure: Patient and parent satisfaction, secondaryOutcomes measure: Crown retention, secondaryOutcomes measure: Gingival inflammation, secondaryOutcomes measure: Color match, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: National Research Centre, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06305832, orgStudyIdInfo id: IUNU-PC-120, briefTitle: Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-07, primaryCompletionDateStruct date: 2028-03, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP)., conditionsModule conditions: Prostate Cancer, conditions: Biochemical Recurrence, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 102, type: ESTIMATED, armsInterventionsModule interventions name: Rezvilutamide, interventions name: Androgen deprivation therapy (ADT), interventions name: SRT, outcomesModule primaryOutcomes measure: 3-year biochemical progression-free survival, secondaryOutcomes measure: progression-free survival (PFS), secondaryOutcomes measure: metastasis-free survival (MFS), secondaryOutcomes measure: percentage of undetectable PSA, secondaryOutcomes measure: ctDNA-positive rate, secondaryOutcomes measure: ctDNA clearance rate, secondaryOutcomes measure: Adverse Events, eligibilityModule sex: MALE, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210000, country: China, contacts name: Shun Zhang, role: CONTACT, phone: 15050589789, phoneExt: 15050589789, email: explorershun@126.com, geoPoint lat: 32.06167, lon: 118.77778, locations facility: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210000, country: China, contacts name: Hongqian Guo, Phd, role: CONTACT, phone: 13605171690, email: dr.ghq@nju.edu.cn, contacts name: Shun Zhang, role: CONTACT, contacts name: Hongqian Guo, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06305715, orgStudyIdInfo id: IIT-THOMPSON-RADIANCE-LUNG-X, briefTitle: Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2027-06-15, completionDateStruct date: 2028-06-15, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Medical College of Wisconsin, class: OTHER, descriptionModule briefSummary: This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the use of definitive radiation to the primary lung lesion prolongs progression-free survival (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC) patients who are subsequently placed on a tyrosine kinase inhibitor (TKI)., conditionsModule conditions: Non Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 34, type: ESTIMATED, armsInterventionsModule interventions name: Radiation Therapy, interventions name: Targeted TKI therapy, outcomesModule primaryOutcomes measure: Progression Free Survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Froedtert Hospital & the Medical College of Wisconsin, city: Milwaukee, state: Wisconsin, zip: 53226, country: United States, contacts name: Jonathan Thompson, MD, MS, role: CONTACT, phone: 414-805-4600, email: jrthomps@mcw.edu, geoPoint lat: 43.0389, lon: -87.90647, hasResults: False
protocolSection identificationModule nctId: NCT06305702, orgStudyIdInfo id: LZRXN-001, briefTitle: Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-07-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-01-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Liaoning Tumor Hospital & Institute, class: OTHER, descriptionModule briefSummary: A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy., conditionsModule conditions: HER2-positive Metastatic Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 500, type: ACTUAL, armsInterventionsModule interventions name: inetetamab, outcomesModule primaryOutcomes measure: Progression Free Survival(PFS), secondaryOutcomes measure: objective response rate (ORR), secondaryOutcomes measure: Adverse events (AEs), eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Liaoning Cancer Hospital &Institue, city: Shenyang, country: China, geoPoint lat: 41.79222, lon: 123.43278, hasResults: False
protocolSection identificationModule nctId: NCT06305676, orgStudyIdInfo id: MCC-23073, briefTitle: Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC), acronym: BASH OPC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-22, primaryCompletionDateStruct date: 2029-01, completionDateStruct date: 2029-01, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: H. Lee Moffitt Cancer Center and Research Institute, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, age, race/ethnicity, and tobacco use collected from the Moffitt Cancer Center (Moffitt) and the University of Pittsburgh Medical Center Hillman Cancer Center (Pittsburgh)., conditionsModule conditions: Oropharyngeal Cancer, conditions: HPV-Related Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: combined HPV 16 DNA and host gene methylation oral biomarker panel, outcomesModule primaryOutcomes measure: Diagnostic Sensitivity, primaryOutcomes measure: Diagnostic Specificity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Moffitt Cancer Center, status: RECRUITING, city: Tampa, state: Florida, zip: 33612, country: United States, contacts name: Kimberly Isaacs-Soriano, role: CONTACT, phone: 813-745-6992, email: kimberly.Isaacs-Soriano@moffitt.org, contacts name: Anna Giuliano, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Antonio Amelio, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Jimmy Caudell, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Christine Chung, MD, role: SUB_INVESTIGATOR, contacts name: Bruce Wenig, MD, role: SUB_INVESTIGATOR, geoPoint lat: 27.94752, lon: -82.45843, locations facility: University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, status: RECRUITING, city: Pittsburgh, state: Pennsylvania, zip: 15232, country: United States, contacts name: Jose P. Zevallos, MD, PhD, role: CONTACT, email: zevallosjp@upmc.edu, contacts name: Robert Ferris, PhD, role: CONTACT, email: ferrrl@UPMC.EDU, geoPoint lat: 40.44062, lon: -79.99589, hasResults: False
protocolSection identificationModule nctId: NCT06305663, orgStudyIdInfo id: 921, briefTitle: A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-29, primaryCompletionDateStruct date: 2027-01-31, completionDateStruct date: 2027-01-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Bausch & Lomb Incorporated, class: INDUSTRY, descriptionModule briefSummary: A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children, conditionsModule conditions: Myopia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: The identity of the study eye will be masked to subjects, assessors, and other masked personnel while masking is maintained.., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 418, type: ESTIMATED, armsInterventionsModule interventions name: Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic), interventions name: CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens, outcomesModule primaryOutcomes measure: Mean change from baseline in axial length., primaryOutcomes measure: Mean change from baseline in cycloplegic SERE., eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Site 105, city: Beijing, state: Beijing, zip: 100044, country: China, geoPoint lat: 39.9075, lon: 116.39723, locations facility: Site 107, city: Dongcheng, state: Beijing, zip: 100730, country: China, locations facility: Site 109, city: Xiamen, state: Fujian, zip: 361004, country: China, geoPoint lat: 24.47979, lon: 118.08187, locations facility: Site 111, city: Haikou, state: Hainan, zip: 570311, country: China, geoPoint lat: 20.04583, lon: 110.34167, locations facility: Site 110, city: Wuhan, state: Hubei, zip: 430012, country: China, geoPoint lat: 30.58333, lon: 114.26667, locations facility: Site 102, city: Shanghai, state: Shanghai, zip: 200433, country: China, geoPoint lat: 31.22222, lon: 121.45806, locations facility: Site 106, city: Taiyuan, state: Shanxi, zip: 030072, country: China, geoPoint lat: 37.86944, lon: 112.56028, locations facility: Site 108, city: Shenzhen, state: Shenzhen, zip: 518040, country: China, geoPoint lat: 22.54554, lon: 114.0683, locations facility: Site 103, city: Chengdu, state: Sichaun Province, zip: 610044, country: China, geoPoint lat: 30.66667, lon: 104.06667, locations facility: Site 104, city: Nankai, state: Tianjin, zip: 300392, country: China, locations facility: Site 101, city: Wenzhou, state: Zhejiang, zip: 325027, country: China, geoPoint lat: 27.99942, lon: 120.66682, hasResults: False
protocolSection identificationModule nctId: NCT06305650, orgStudyIdInfo id: WK2024001, briefTitle: Probiotic Influence on Obesity-Related Lipidemia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-06-20, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Wecare Probiotics Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults. Specifically, it will assess the probiotic's impact on body composition metrics such as BMI, body fat percentage, WHR, and BMR. The inclusion criteria for participants are a BMI of ≥28 kg/m\^2, targeting individuals who stand to benefit significantly from metabolic and body composition improvements., conditionsModule conditions: Overweight or Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Double（Participant,Investigator）, whoMasked: PARTICIPANT, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: Probiotic, outcomesModule primaryOutcomes measure: Effect on body mass index (BMI) values., eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Henan University of Science and Technology, status: RECRUITING, city: Luoyang, state: Henan, zip: 471000, country: China, contacts name: Ying Wu, Dr., role: CONTACT, phone: +86 18639283502, email: wuying2000@126.com, geoPoint lat: 34.68361, lon: 112.45361, hasResults: False